URO17 Bladder Cancer Test
Accurate, Cost Effective, Non-Invasive – FDA Designated “Breakthrough Device” Significant New Revenue Stream
> 95% Sensitivity, > 90% Specificity, 100% NPV, 91% PPV
Detects both high and low grade bladder cancer
Risk stratification tool for additional workup (i.e., Cystoscopy, UroVysion™ FISH)